PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Comago

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Lonza and OrganoBalance Enter Global License Agreement - Lonza and ORGANOBALANCE enter global license agreement to develop and market unique probiotic, Lactobacillus anti-H. pylori - OrganoBalance.com
Lonza and OrganoBalance Enter Global License Agreement

 

NewswireToday - /newswire/ - Falkensee, Brandenburg, Germany, 2011/04/19 - Lonza and ORGANOBALANCE enter global license agreement to develop and market unique probiotic, Lactobacillus anti-H. pylori - OrganoBalance.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Lonza and ORGANOBALANCE today announced the signing of a worldwide exclusive license agreement in which Lonza will develop, produce and commercialize products containing a probiotic Lactobacillus strain. Developed by ORGANOBALANCE GmbH, the probiotic strain acts against Helicobacter pylori (H. pylori). Research shows that H. pylori has been implicated as a common cause of peptic ulcers and gastritis.

Currently, about 50 percent of the global population is infected with H. pylori (Source: Czinn SJ. J Pediatr. 2005 Mar;146 (3 Suppl):S21-6.). However, this new probiotic strain demonstrates great potential in helping to maintain a balanced H. pylori concentration. Utilizing a unique patent-protected mode of action, Lactobacillus anti-H. pylori binds to H. pylori in the stomach, thus creating large aggregates, which are subsequently flushed out of the stomach and excreted.
“This agreement with ORGANOBALANCE creates a basis for Lonza to enter the probiotic market - a market with vast growth potential - with a unique ingredient,” said Roman Quinter, Senior Vice President and Head of Nutrition Ingredients business for Lonza. “Lonza is a global leader in the manufacturing of intermediates and API’s for the pharmaceutical industry through biotechnology and fermentation. Integrating the Lactobacillus Anti-H. pylori strain into our nutrition ingredient portfolio provides an opportunity to leverage our strong biotech expertise and knowledge to provide a highly effective product to the nutrition landscape.“

Produced via a fermentation process, the Lactobacillus anti-H. pylori strain is patent-protected. The strain demonstrates probiotic activity by gently, yet highly effectively, removing H. pylori from the stomach.

“As the leader in the development of innovative probiotic strains, we regard this agreement with Lonza as a further recognition of ORGANOBALANCE’s strategy, our expertise, and our innovative capacity,” said Prof. Dr. Christine Lang, CEO of ORGANOBALANCE GmbH. “We highly appreciate Lonza’s dedication to lead our development into great success on the nutrition marketplace.”

About Lonza
Lonza (lonza.com) is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion.

About ORGANOBALANCE
ORGANOBALANCE GmbH (organobalance.com) is a company specialising in strain development and microbiological screening, tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. In close cooperation with renowned industry partners, ORGANOBALANCE GmbH develops new biological products in the fields of pharmaceutics, preventive health care, nutrition and cosmetics. In its development activities the company draws on its own collection of more than 8000 microorganisms suitable for use in foodstuffs as well as its own OASSYS® screening systems. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany.

For further information please contact:
Lonza Ltd
Adriana Williams, Marketing Manager Nutrition
T: +41 61 316 8626 / F: + 41 61 316 9626 / E: adriana.williams[.]lonza.com.

Lonza Group
Melanie Disa, Head of External Communications
T: +1 201 316 9413 / F: +1 201 696 3533 / E: melanie.disa[.]lonza.com.

ORGANOBALANCE GmbH
Kristin Ebert
Gustav-Meyer-Allee 25
13355 Berlin - Germany
T: +49 30 46307-200 / F: +49 30 46307-210 / E: info[.]organobalance.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Comago

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Lonza and OrganoBalance Enter Global License Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Helmut Landenberger - Comago.de 
+49 33 22 84 06 52 mail[.]comago.de
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Comago securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Comago / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)